MESO · NASDAQ
Mesoblast (MESO) Stock Price & Fundamentals
Mesoblast (MESO) closed at $656.64 on Oct 9, 2026, up 1.04% from the previous close of $649.91.
Share price, past year
1Y +6.58%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $656.64 |
| Sep 30, 2026 | $637.86 |
| Aug 31, 2026 | $630.73 |
| Jul 31, 2026 | $614.47 |
| Jun 30, 2026 | $675.99 |
| May 29, 2026 | $688.93 |
| Apr 30, 2026 | $669.73 |
| Mar 31, 2026 | $658.89 |
| Feb 27, 2026 | $624.26 |
| Jan 30, 2026 | $609.10 |
| Dec 31, 2025 | $611.03 |
| Nov 28, 2025 | $617.56 |
| Oct 31, 2025 | $588.33 |
Key statistics
- Market cap
- —
- P/E (TTM)
- —
- EPS (TTM)
- —
- Revenue (TTM)
- —
- Net income (TTM)
- —
- Shares outstanding
- 1.3B
- Dividend yield
- —
- 52-week range
- $584.78 – $691.90
Market cap, P/E and dividend yield aren't shown for Mesoblast yet: its SEC filings count its ordinary shares, which can differ from the shares traded in the US.
Financials
Mesoblast reported revenue of $17.20M for fiscal 2025, up 191.39% from fiscal 2024.
Mesoblast reported a net loss of $102.14M in fiscal 2025.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2025ended Jun 30, 2025 | $17.20M | +191.4% | −$102.14M | −593.9% | −$0.0846 | −$50.63M |
| FY2024ended Jun 30, 2024 | $5.90M | −21.3% | −$87.96M | −1,490.3% | −$0.0891 | −$48.73M |
| FY2023ended Jun 30, 2023 | $7.50M | −26.5% | −$81.89M | −1,091.7% | −$0.1053 | −$63.53M |
| FY2022ended Jun 30, 2022 | $10.21M | +37.4% | −$91.35M | −894.6% | −$0.1338 | — |
| FY2021ended Jun 30, 2021 | $7.43M | −76.9% | −$98.81M | −1,329.2% | −$0.1633 | — |
| FY2020ended Jun 30, 2020 | $32.16M | +92.3% | −$77.94M | −242.4% | −$0.1474 | — |
| FY2019ended Jun 30, 2019 | $16.72M | −3.6% | −$89.80M | −537.0% | −$0.1816 | — |
| FY2018ended Jun 30, 2018 | $17.34M | +619.0% | −$35.29M | −203.5% | −$0.0758 | — |
| FY2017ended Jun 30, 2017 | $2.41M | −94.3% | −$76.82M | −3,184.7% | −$0.1925 | — |
| FY2016ended Jun 30, 2016 | $42.55M | — | −$4.13M | −9.7% | −$0.0113 | — |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q4 FY2023ended Jun 30, 2023 | $1.93M | −$21.92M | −$0.0225 |
| Q3 FY2023ended Mar 31, 2023 | $1.94M | −$18.60M | −$0.0253 |
| Q2 FY2023ended Dec 31, 2022 | $2.13M | −$24.49M | −$0.0332 |
| Q1 FY2023ended Sep 30, 2022 | $1.50M | −$16.88M | −$0.0243 |
| Q4 FY2022ended Jun 30, 2022 | $2.22M | −$21.46M | −$0.0261 |
| Q3 FY2022ended Mar 31, 2022 | $2.01M | −$21.30M | −$0.0328 |
| Q2 FY2022ended Dec 31, 2021 | $2.38M | −$25.95M | −$0.04 |
| Q1 FY2022ended Sep 30, 2021 | $3.59M | −$22.65M | −$0.0349 |
Company profile
- Name
- Mesoblast Limited
- Ticker
- MESO
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Biological Products, (No Diagnostic Substances)
- Headquarters
- Level 38, 55 Collins Street, Melbourne, Victoria, C3 3000
- Incorporated in
- C3
- Fiscal year ends
- June
- SEC CIK
- 0001345099
Recent SEC filings
- Aug 27, 2026
- Aug 29, 2025
- Aug 29, 2024
- Aug 31, 2023
- Aug 31, 2022
- Aug 31, 2021
- Sep 3, 2020
- Sep 9, 2019
Frequently asked questions
What is Mesoblast's stock price?
Mesoblast (MESO) closed at $656.64 on Oct 9, 2026, up 1.04% from the previous close of $649.91.
How much revenue does Mesoblast make?
Mesoblast reported revenue of $17.20M for fiscal 2025, up 191.39% from fiscal 2024.
Sources and methodology
Fundamentals come from Mesoblast Limited's filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures